[Updated 7/2/15, 2:55 p.m. See below.] The long-expected approval of Vertex Pharmaceuticals’ new combination drug for cystic fibrosis is finally here. The FDA approved the therapy regimen in a letter it sent to the Boston-based company Thursday.
The drug’s approval... Read more »
Biogen’s revitalized interest in gene therapy continues with a deal the Cambridge, MA-based biotech giant announced this morning.
Biogen has agreed to pay $124 million upfront (including about $30 million that came as an equity investment) and as much as $1.1... Read more »
Bikes are hot. The sharing economy is hot. So Zagster is hot.
The Cambridge, MA-based bicycle-sharing company said today it has raised $3.5 million in new venture funding. The money comes from previous investors LaunchCapital, Fontinalis Partners, Clean Energy Venture Group,... Read more »
[Updated 7/2/15, 10:38 am. See below.] Finding new drugs can be challenging, time consuming, and expensive. But Cambridge, MA, drug discovery company XRpro Sciences believes it can make the process faster and more efficient, and it’s scooping up some... Read more »
Cisco is paying $635 million for privately held OpenDNS, a company founded in 2005 by David Ulevitch, to further build out its cloud-based security business. But the deal is also a sign of the times, according to a prominent player... Read more »
Cybersecurity and healthcare IT are both burgeoning areas of business. Put them together and you have a volatile mix of emerging technologies, security and privacy risks, and regulatory requirements—but also a lot of opportunity for growth and improvements.
It’s no surprise... Read more »
Coders may be used to hacking problems related to phishing, but one international contest that a group from Boston is hoping to win is tackling fishing itself.
Four Bostonians have written algorithms and built a prototype buoy that is intended to... Read more »
Amag Pharmaceuticals is trying to climb out of a midlife crisis, and it’s using acquisitions to do so.
The Waltham, MA-based company split from long-time CEO Brian Pereira in 2011, a few weeks after its ill-fated attempt to merge... Read more »
[Updated 6/29/15 7:00 pm. See below.] It seemed only a matter of time. One of biotech’s most aggressive deal makers, Celgene (NASDAQ: CELG) has struck a wide-ranging, billion-dollar partnership with one of biotech’s highest-profile drug makers, Juno Therapeutics... Read more »
The race to produce a drug to treat and perhaps cure one version of the rare Duchenne muscular dystrophy remains neck and neck. The entrants, BioMarin Pharmaceutical (NASDAQ: BMRN) and Sarepta Therapeutics (NASDAQ: SRPT), both had updates this morning... Read more »